ABSI NASDAQ
Absci Corporation
1W: -13.6%
1M: +17.2%
3M: +71.5%
YTD: +28.2%
1Y: +60.8%
3Y: +270.4%
$4.95
+0.32 (+6.91%)
Weekly Expected Move ±16.9%
$3
$4
$5
$6
$7
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$0.8M
Congress—
ETF Holdings—
Key Statistics
Market Cap$771.7M
52W Range2.24-6.72
Volume3,408,922
Avg Volume4,405,942
Beta2.38
Dividend—
Analyst Ratings
Company Info
CEOSean McClain
Employees156
SectorHealthcare
IndustryBiotechnology
IPO Date2021-07-22
Websiteabsci.com
18105 SE Mill Plain Boulevard
Vancouver, WA 98683
US
Vancouver, WA 98683
US
360 949 1041
About Absci Corporation
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Latest News
AMD Reveals A $6.5 Million Marvell Bet That's Already Soaring
12 Health Care Stocks Moving In Friday's Pre-Market Session
Absci outlines ABS-201 interim 13-week data in H2 2026 while adding ABS-202 and funding plans into H1 2028
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates
Absci (ABSI) Q1 2026 Earnings Call Transcript
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Pangalos Menelas N | P-Purchase | 37,453 | $5.36 | 2026-05-13 |
| Busch Andreas | P-Purchase | 100,000 | $2.29 | 2026-03-12 |
| Walker Shelby J. | F-InKind | 9,825 | $2.80 | 2026-03-03 |
| McClain Sean | F-InKind | 25,316 | $2.80 | 2026-03-03 |
| Bedrick Todd | F-InKind | 5,282 | $2.80 | 2026-03-03 |